Aurinia Pharmaceuticals

Akebia Therapeutics

Ardelyx Inc

Travere Therapeutics

Cara Therapeutics

Vera Therapeutics

Cadrenal Therapeutics, Inc.

ProKidney Corp. Class A

Nephros, Inc.

Dilution score: 25/100 (LOW), 29.8 months cash

13F fund flow: neutral, 25 institutional managers

Brevan Howard

Acadian

Millennium

Two Sigma

Balyasny

ExodusPoint

State Street

Franklin Templeton

Schonfeld

152 PubMed publications found for Aurinia

Belimumab outperforms placebo for attainment of modified DORIS remission and LLDAS without the glucocorticoid component: a post hoc analysis of five phase III SLE trials.

Emerging treatments for Sjögren's disease: promising drugs on the horizon.

Belimumab induces early and sustained resolution of lupus thrombocytopenia.

Efficacy and safety of the CD40 ligand inhibitor dapirolizumab pegol in systemic lupus erythematosus (PHOENYCS GO): a randomised, double-blind, placebo-controlled, phase 3 trial.

Anifrolumab Dose Regimen Selection for a Phase 3 Trial in Lupus Nephritis.

Short interest: 7.6% of float, squeeze risk: MODERATE

SW convergence: 69/100 (Bullish Convergence), 3 bullish / 0 bearish signals

<article class="bts-verified-summary" data-ticker="AUPH">
<p>Aurinia Pharmaceuticals (AUPH) has no currently recruiting or active clinical trials where it is listed as lead sponsor on ClinicalTrials.gov.</p>
<p>No Form 4 insider filings for AUPH were recorded at the SEC in the past 30 days<sup><a href="#fn-1">[1]</a></sup>.</p>
<section class="sources"><h3>Sources</h3><ol><li id="fn-1">SEC EDGAR, 0001600620. Source last updated 2026-04-10, retrieved 2026-04-10. <a href="https://efts.sec.gov/LATEST/search-index?q=%22AUPH%22&amp;forms=4&amp;dateRange=custom&amp;startdt=2026-03-11&amp;enddt=2026-04-10" rel="nofollow noopener">link</a></li></ol></section>
</article>

SEC EDGAR — 0001600620

Aurinia Pharmaceuticals (AUPH) — BioTechSigns Verified Summary

Aurinia Pharmaceuticals (AUPH) has no currently recruiting or active clinical trials where it is listed as lead sponsor on ClinicalTrials.gov.

No Form 4 insider filings for AUPH were recorded at the SEC in the past 30 days[1].

Sources:
[1] SEC EDGAR, 0001600620. Source last updated 2026-04-10, retrieved 2026-04-10.
    https://efts.sec.gov/LATEST/search-index?q=%22AUPH%22&forms=4&dateRange=custom&startdt=2026-03-11&enddt=2026-04-10